Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

BACKGROUND AND PURPOSE: Impaired ambulation is a prominent disabling symptom of multiple sclerosis and can lead to reduced quality of life. Whether natalizumab, a monoclonal antibody shown to reduce disease activity in relapsing−remitting multiple sclerosis, could impact ambulation performance was e...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Eur J Neurol
Autores principales: Voloshyna, N, Havrdová, E, Hutchinson, M, Nehrych, T, You, X, Belachew, S, Hotermans, C, Paes, D
Formato: Artigo
Lenguaje:Inglês
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4365753/
https://ncbi.nlm.nih.gov/pubmed/25511792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ene.12618
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares